Nashville Biosciences is a clinical big data & genomics
company accelerating the R&D activity of partners in the
biopharmaceutical, diagnostics, and AI industries.

 

Keep In Touch

GeoWolf brings new possibilities
for staying connected with friends.

WHO WE ARE

Our History

Genomics is one of the fastest developing research areas in the world today. Due to rapid advancements, in-depth genetic analysis has become essential in R&D and clinical practice.

With drug development costs forecast to double every nine years, we need more than ever to improve R&D productivity and uncover new ways to diagnose and care for diseases more efficiently. In order to increase the speed-to-market for life sciences companies, it’s imperative that we fully recognize and capture the potential of human genetics in drug and diagnostics R&D.

Understanding the Complex Relationship Between Genes and Disease

At Nashville Biosciences, we are gaining valuable genetic insights through BioVU®, a biobank of millions of longitudinal medical records spanning over 10 years with hundreds of thousands of matched genetic samples. Created at Vanderbilt University Medical Center and Vanderbilt University, BioVU® is a biorepository of DNA extracted from discarded blood collected during routine clinical testing. Through the use of Nashville Biosciences’ advanced technology and novel algorithms, the team is discovering important genetic associations and identifying genes that contribute to help advance the R&D efforts of our partners.

Transforming the DNA of Life Science Research and Development

As a subsidiary of Vanderbilt University Medical Center, Nashville Biosciences is partnering with the healthcare industry to leverage the power of BioVU® and provide unparalleled clinical insight, resources, and expertise to a wide range of R&D challenges.

OUR PEOPLE

Meet the Team

The Nashville Biosciences team is comprised of industry veterans, physicians and scientists dedicated to serving our clients.

Leeland Ekstrom, Ph.D.

Founder & Chief Operating Officer

Elizabeth Ann Stringer, Ph.D.

Chief Scientific Officer

James Stover, Ph.D.

Chief Business Officer

Judsen Schneider, Ph.D.

Chief Technology Officer

Karen Nanney

Secretary, Treasurer & Chief Financial Officer

Spencer Andrei

Marketing Associate

Seth Belcher

Business Development - East Coast

Steven Held, MD

Medical Director

Mike Leuze

Senior Computational Biologist

Phil LoCascio, Ph.D.

Senior Computational Biologist

Kai Smith

Application Developer

Erin Sundaram, Ph.D.

Senior Genomic Scientist

Lakshmi Sundarajan, Ph.D.

Genomic Scientist

Ed Uberbacher, Ph.D.

Director of Bioinformatics

Emanuel Villa

Data Engineer

Jamie Wenke, Ph.D.

Senior Genomics Scientist

Yiyang Wu, MD, Ph.D.

Genomics Scientist

Joanne Johnson

Office Manager

Shanon Simons, CPA

Director of Finance and Controller

Hero Wu, Canine Ph.D.

Office Mascot

Jon Duane, M.B.A.

Executive Chairman
Senior Partner Emeritus, McKinsey & Company

Gordon R. Bernard, M.D.

Melinda Owen Bass Professor of Medicine, EVP for Research and Director of Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center

Sam Lynch, D.M.D., D.M.Sc.

President and CEO, Lynch Biologics; Immediate Past Chairman, Life Sciences Tennessee

John F. Manning, Jr., Ph.D., M.B.A.

Chief Operating Officer and Corporate Chief of Staff, Vanderbilt University Medical Center

Susan R. Wente, Ph.D.

Interim Chancellor and Provost

VANDERBILT SCIENTIFIC ADVISORS

Nancy J. Cox, Ph.D.

Mary Phillips Edmonds Gray Professor of Genetics
Professor of Medicine
Director, Vanderbilt Genetics Institute
Director, Division of Genetic Medicine
Vanderbilt University Medical Center

Lawrence J. Marnett, PhD.

Dean of Basic Sciences, School of Medicine
Mary Geddes Stahlman Professor of Cancer Research
Director, A.B. Hancock Jr. Memorial Laboratory
Professor of Biochemistry, Chemistry and Pharmacology
Vanderbilt University

Dan M. Roden, M.D.C.M.

Director, Oates Institute for Experimental Therapeutics
Assistant Vice Chancellor for Personalized Medicine
Sam Clark Professor of Experimental Therapeutics
Professor of Medicine & Pharmacology
Vanderbilt University Medical Center

Yu Shyr, Ph.D

Harold L. Moses Chair in Cancer Research
Chair, Department of Biostatistics
Director, Vanderbilt Center for Quantitative Sciences
Director, Vanderbilt Technologies for Advanced Genomics Analysis and Research Design
Professor of Biostatistics, Biomedical Informatics, and Health Policy
Vanderbilt University Medical Center

OUR PROMISE

Unwavering Commitment to Patient Privacy

Patient welfare is a top priority for Nashville Biosciences and as such, we are committed to transparency in our practices and ensuring the protection of patient data.

Prior to any blood test, patients are provided with information about BioVU®, its research and goals. After learning about the program, patients are presented with a consent form in which they can either choose to donate their leftover blood sample or decline to participate. If a patient does not want to donate any leftover samples to BioVU®, they simply do not sign the form. If a patient consents to share his or her leftover samples with BioVU® and is a match for current research programs, BioVU® removes all personally identifiable information from the sample and medical record, then stores it in a safe and secure location. Additionally, if a patient changes their mind after signing the BioVU® consent form, they can call a BioVU® helpline to withdraw their participation from any future research.

Nashville Biosciences, Vanderbilt University Medical Center, and BioVU® regularly engage experts in ethics, science and research, operations, data security, and patient advocacy, among others, to ensure the accessibility and transparency of our information and to inform engagement with all stakeholders, including patients.

The NashBio™ Technology

Introduction to BioVU®

An Unparalleled Resource for Improving Human Health

BioVU® is a bio-bank of de-identified longitudinal medical records and DNA extracted from discarded blood samples collected during routine clinical care designed to enable exploration of the relationships among genetic variation, disease susceptibility and variable drug responses.

The NashBio™ Technology

Introduction to PheWAS™

Creating News Means of Diagnosing, Treating and Preventing Disease

Drug discovery traditionally has been approached by attempting to identify the genes or targets underlying the disease of interest and then identifying a molecule that interacts with that target. With this approach, we don’t always understand the disease process or how the drug target is implicated in the disease. The pursuit of new targets is also difficult.

The pheWAS™ approach increases the probability of R&D success by leveraging natural genetic ‘experiments’ within human DNA. We use small mutations naturally present in each and every human genome, and correlate those mutations to the full disease landscape. This ‘target-first’ approach allows us to map out diseases that may be treated by a new drug or potential sides effects that may occur.